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Juliya V. Kharchenko, Oleksandr S. Detistov,* and Valeriy D. Orlov
Chemical Department, V.N. Karazin KharkiV National UniVersity, 4 SVoboda Sq.,
KharkiV 61077, Ukraine
ReceiVed July 2, 2008
We have developed a liquid-phase route for combinatorial synthesis of novel substituted 5-(1,2,4-oxadiazol-
5-yl)-3,4-dihydropyrimidine-2(1H)-thiones. Biginelli-type three-component condensation of 1-(3-aryl-1,2,4-
oxadiazol-5-yl)acetones, thiourea, and benzaldehydes is shown to result in new 5-(1,2,4-oxadiazol-5-yl)-
3,4-dihydropyrimidine-2(1H)-thione heterocyclic system. If salicylaldehydes are used in this reaction, a
mixture of 5-(1,2,4-oxadiazol-5-yl)-3,4-dihydropyrimidine-2(1H)-thiones and 11-(1,2,4-oxadiazol-5-yl)-
2,3,5,6-tetrahydro-4H-2,6-methano-1,3,5-benzoxadiazocine-4-thiones is formed.
Introduction
Multicomponent reactions (MCRs) are in general of
increasing importance in organic and medicinal chemistry.1
Now, when the drug discovery strongly requires speed,
diversity, and efficiency, MCR strategies offer significant
advantages over conventional linear-type syntheses.2 The
Biginelli protocol is particularly attractive because the
resulting dihydropyrimidine (DHPM) scaffold displays a
wide range of biological activities, which has led to the
development of a number of leading compounds based on
that structural core.3 Recent publications on Biginelli-type
reactions describe the use of different catalysts,4,5 micro-
wave,6 and ultrasound7 irradiations. On the other hand,
substances containing a disubstituted 1,2,4-oxadiazoles frag-
ment are frequently used in drug discovery as an important
bioisostere for esters and amides to improve pharmacokinetic
properties of drug candidates.8 Oxadiazoles have been being
the subject of investigation in a number of different
therapeutic areas, usually as a replacement for ester or amide
functional groups. 1,2,4-Oxadiazoles have been proposed as
muscarinic receptor agonist,9,10 benzodiazepine receptor
agonist,11 histamine H3 receptor antagonist,12 and antiviral
compounds.13 This paper presents a new library of 5-(1,2,4-
oxadiazol-5-yl)-3,4-dihydropyrimidine-2(1H)-thiones; it in-
cludes 70 substances obtained by the three-component
condensation of the Biginelli type.
Results and Discussion
Below we describe a new liquid-phase parallel synthesis
of the library of compounds 1 (Figure 1).
Our approach is based on the condensation of 1-(3-aryl-
1,2,4-oxadiazol-5-yl)acetones 2, thiourea 3 and aromatic
aldehydes 4, which is carried out under the classic Biginelli
reaction conditions.
We started with chemsets 2A-G obtained by the reaction
of arylamidoximes 5A-G with 2,2,6-trimethyl-4H-1,3-
dioxin-4-one 6 (Scheme 1). Chemsets 5A-G were obtained
using the reported method.14
The synthesis of building blocks 2A-G was carried out in
dioxane with triethylamine as the catalyst. Yields of target
products are satisfactory (32-64%) (Figure 2, Table 1).
In 1H NMR spectra of compounds 2A-G, the signals of
methyl and methylene groups are observed at 2.20-2.30 and
4.40-4.55 ppm correspondingly. All other proton signals
are observed at their usual positions.
Biginelli-type three-component condensation of building
blocks 2A-G, thiourea 3, and benzaldehydes 4a-j (Figure
3) leads to the formation of dihydropyrimidines 1A-G,a-j
* To whom correspondence should be addressed. E-mail: DeAS@
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Figure 1. 5-(1,2,4-Oxadiazol-5-yl)-3,4-dihydropyrimidine-2(1H)-
thiones, 1.
Table 1. Yields of Building Blocks 2A-G
substance yield, %
2A 32
2B 41
2C 39
2D 47
2E 51
2F 64
2G 56
Scheme 1. Synthesis of 1-(3-Aryl-1,2,4-oxadiazol-5-yl)acetones,
2A-G
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(Scheme 2, Figure 4). The yields of products are different
depending on the structure of initial reagents. Thus, if
electron-releasing groups are in para-positions of R1 and R2
substitutes in scaffold 1, the yields of the target products
are high. If, alternatively, R1 and R2 substitutes have no
electron-releasing groups or if positions of these groups are
different, yields of products decrease to good and seldom to
satisfactory.
Dihydropyrimidines 1 were characterized by 1H NMR, 13C
NMR, DEPT, and LC/MS analysis. The 1H, 13C NMR, and
DEPT spectra confirm the suggested structures. According
to the LC/MS data, all the synthesized compounds were more
than 90% pure. Results of the element analysis are in
accordance with theoretical considerations. This complex of
experimental data proofs the purity of obtained substances.
In 1H NMR spectra the proton H4 in 3,4-dihydropyrimidine-
2(1H)-thione structures 1 is clearly observed as singlet in
the range of δ 5.35-5.55 ppm. The protons NH are observed
as singlets in two ranges of δ 10.60-10.80 and 9.60-9.90
ppm. All other proton signals are observed in their usual
resonance areas.
We also studied the three-componentcondensation of
chemset 2A-G, thiourea 3, and salicylaldehydes 4k, l
(Figure 5). As a rule, thin-layer chromatography (TLC)
showed the formation of mixtures of dihydropyrimidines 1
and methanobenzoxadiazocines 7 under the reaction condi-
tions (Scheme 3).
Sporadically pure dihydropyrimidines 1 and methanoben-
zoxadiazocines 7 were formed. Thus, in the case of salicylal-
dehyde 4k and building block 2A, pure compound 1Ak was
formed; in the case of salicylaldehyde 4l and building blocks
2B, D, pure compounds 7Bl, 7Dl were formed (Figure 6).
The formation of methanobenzoxadiazocine heterocyclic
system was proved for compound 7Bl by 1H NMR, 13C
NMR, and DEPT analysis. In 1H NMR spectra of this
substance, the signals of 4 protons of methanobenzoxadia-
Figure 2. Selected 1-(3-aryl-1,2,4-oxadiazol-5-yl)acetones 2A-G for library design.
Figure 3. Selected benzaldehydes 4a-j for library design.
Figure 4. Examples of 5-(1,2,4-oxadiazol-5-yl)-3,4-dihydropyrimidine-2(1H)-thiones synthesized, 1.
Figure 5. Salicylaldehyde inputs 4k, l.
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zocine moiety were observed: two protons NH in the ranges
of δ 9.30-9.40 and 9.55-9.65 ppm, the proton H6 in the
range 5.40-5.45 ppm, and the proton H11 in the range
4.30-4.35 ppm. The signal of proton H11 is characteristic
for methanobenzoxadiazocine heterocyclic system: it is
absent in 1H NMR spectra of dihydropyrimidine with
2-hydroxyphenyl substitute 1Ak, whereas proton OH is
observed as singlet in the range of δ 9.25-9.30 ppm. 1H
NMR spectra of all other substances of this series show
complex signals of both proton H11 of methanobenzoxa-
diazocine heterocyclic system and proton OH of substitutes
at dihydropyrimidines core. The 1H, 13C NMR, and DEPT
spectra of substances 7Bl and 1Ak confirm the offered
structures.
Conclusions
An efficient synthetic route has been developed for the
combinatorial synthesis of novel 5-(1,2,4-oxadiazol-5-yl)-
3,4-dihydropyrimidine-2(1H)-thione library in solution. It is
based on the Biginelli-type three-component condensation
of 1-(3-aryl-1,2,4-oxadiazol-5-yl)acetones, thiourea, and
aromatic aldehydes. Substances with low levels of impurities
were obtained using a simple crystallization from the reaction
mixtures. Product yields varied depending on the reactant
structures, but in most cases, the desired products were
obtained with high and good yields. The three-component
condensation of 1-(3-aryl-1,2,4-oxadiazol-5-yl)acetones, thio-
urea and salicylaldehydes was also studied. As a rule, the
mixture of 5-(1,2,4-oxadiazol-5-yl)-3,4-dihydropyrimidine-
2(1H)-thiones and 11-(1,2,4-oxadiazol-5-yl)-2,3,5,6-tetrahy-
dro-4H-2,6-methano-1,3,5-benzoxadiazocine-4-thiones was
formed under reaction conditions.
Supporting Information Available. Experimental pro-
cedures, spectroscopic data, references for known com-
pounds, 1H NMR, 13C NMR, and 13C NMR DEPT spectra,
and LC/MS data of synthesized compounds. This material
is available free of charge via the Internet at http://
pubs.acs.org.
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